Skip to main content
. 2023 Jan 20;6(2):306–319. doi: 10.1021/acsptsci.2c00223

Figure 5.

Figure 5

Five months of cemdomespib therapy maintained neuromuscular function in three animal models of CMT1X. Mice were treated with 0.3 mg/kg (A) or 3 mg/kg (B) cemdomespib beginning at 4 months of age (week 0) and grip strength measured biweekly. (A) *, p < 0.0002 versus time-matched T55I-Cx32def vehicle. ^, p < 0.003 versus time-matched Cx32def vehicle. Data are mean ± SD and were analyzed using a two-way ANOVA and Sidak’s test. Data were pooled from two independent cohorts of Cx32def and T55I-Cx32def mice. (B) *, p < 0.001 versus time-matched vehicle. Data are mean ± SD and were analyzed using a mixed-effect analysis and Tukey’s test. (C) Five months of cemdomespib treatment differentially improved grip strength between the genotypes. Red lines, p < 0.0001 versus respective genotype control; blue comparisons, p < 0.0001 versus 3 mg/kg Cx32def; purple comparison p < 0.003 versus 3 mg/kg T55I-Cx32def; *, p < 0.0001 versus 0.3 mg/kg T55I-Cx32def. Data for all groups are mean ± SD. Symbols indicate the response of individual animals in each group.